UMOJA BIOPHARMA
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer. The company's treatment approach retools a patient’s immune system in vivo to direct potent anti-cancer immune cells to a patient’s tumor, augmenting the body’s natural mechanisms for fighting cancer.
UMOJA BIOPHARMA
Industry:
Biopharma Biotechnology Developer Platform Information Technology
Founded:
2019-01-01
Address:
Seattle, Washington, United States
Country:
United States
Website Url:
http://www.umoja-biopharma.com
Total Employee:
101+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
263 M USD
Technology used in webpage:
Euro Google Maps IPv6 ReCAPTCHA Google Google Cloud Akamai Hosted
Similar Organizations
Cytokinetics
Cytokinetics is a biopharmaceutical company developing therapies for debilitating diseases.
Emmaus Medical
Emmaus Medical is a pharmaceutical company developing new treatments for rare diseases and conditions.
Innovent Biologics
Innovent Biologics is a biopharmaceutical company that develops and manufactures monoclonal antibodies.
Simcha Therapeutics
Simcha Therapeutics is a biopharmaceutical company developing engineered cytokine immunotherapy for cancer.
Sirnaomics
Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Investors List
SoftBank Vision Fund
SoftBank Vision Fund investment in Series B - Umoja Biopharma
SVB Securities
SVB Securities investment in Series B - Umoja Biopharma
RTW Investments
RTW Investments investment in Series B - Umoja Biopharma
Presight Capital
Presight Capital investment in Series B - Umoja Biopharma
Cormorant Asset Management
Cormorant Asset Management investment in Series B - Umoja Biopharma
Temasek Holdings
Temasek Holdings investment in Series B - Umoja Biopharma
CaaS Capital Management
CaaS Capital Management investment in Series B - Umoja Biopharma
Qiming Venture Partners USA
Qiming Venture Partners USA investment in Series A - Umoja Biopharma
MPM Capital
MPM Capital investment in Series A - Umoja Biopharma
DCVC Bio
DCVC Bio investment in Series A - Umoja Biopharma
Official Site Inspections
http://www.umoja-biopharma.com Semrush global rank: 1.3 M Semrush visits lastest month: 20.74 K
- Host name: 64.158.196.104.bc.googleusercontent.com
- IP address: 104.196.158.64
- Location: United States
- Latitude: 38.6583
- Longitude: -77.2481
- Timezone: America/New_York
More informations about "Umoja Biopharma"
Umoja Biopharma - Crunchbase Company Profile & Funding
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer. The company's treatment approach retools a patient’s immune …See details»
Looking Back, Looking Ahead: A Letter from Umoja’s CEO
A close second in significance has been our growth and maturation as an organization. We made critical hires onto our senior leadership team, including Nushmia Khokhar as Chief Medical …See details»
Umoja Biopharma - Org Chart, Teams, Culture & Jobs - The Org
View Umoja Biopharma's up-to-date org chart, open roles, and culture details. Find executives, board members, teams, related companies, and more. ... Umoja is developing a new approach …See details»
Umoja Biopharma - BIO International Convention | BIO
The Biotechnology Innovation Organization is the world's largest biotech trade association. Learn about BIO, register for events and explore member services. ... Umoja Biopharma, Inc. is a …See details»
Umoja Biopharma - Funding, Financials, Valuation & Investors
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer. Search Crunchbase. Start Free Trial . Chrome Extension. ... How …See details»
Umoja Biopharma - PitchBook
Umoja Biopharma General Information Description. Provider of immunotherapies intended to transform cancer treatment and improve quality of life. The company's cellular immunotherapy platform uses gene therapy to target cancer cells and …See details»
Umoja Biopharma - Updates, News, Events, Signals & Triggers
Umoja Biopharma, Inc is focused on advancing immunotherapies for cancer treatment. Their research includes developing xenogenic-free methods for generating hematopoietic …See details»
Umoja Biopharma Presents Preclinical Data at the 65th …
SEATTLE, December 11, 2023 – Umoja Biopharma, Inc., a transformative immunotherapy company creating off-the-shelf treatments for cancers and other indications of high unmet need, today announced proof-of-concept preclinical …See details»
Umoja Biopharma Appoints Scott Myers as Chairman of its Board …
Nov 21, 2024 Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop off-the-shelf therapeutics that improve the reach, effectiveness, and access of CAR-T …See details»
Umoja Biopharma - Contacts, Employees, Board Members
Organization. Umoja Biopharma . Connect to CRM . Save . Summary. Financials. People. Technology. Signals & News. Similar Companies. Highlights. Employee Profiles 4. Number of …See details»
Our Pipeline - Umoja Biopharma
1150 Eastlake Ave E, Suite 400 Seattle, WA 98109 [email protected]See details»
Umoja Biopharma Breaks Ground on Extensive ... - Markets Insider
Aug 30, 2021 Umoja Biopharma, Inc. is a preclinical stage company advancing an entirely new approach to immunotherapy designed to retool a patient's immune system in vivo.See details»
Umoja Biopharma and IASO Biotherapeutics Announce Research ...
Nov 21, 2022 Umoja Biopharma and IASO Biotherapeutics Announce Research Collaboration to Bring Off-the-Shelf Therapies to Patients with Hematological Malignancies Umoja Biopharma, …See details»
Umoja Biopharma Announces FDA Clearance of IND Application …
Jul 31, 2024 Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop off-the-shelf therapeutics that improve the reach, effectiveness, and access of CART cell …See details»
AbbVie and Umoja Biopharma Announce Strategic Collaboration …
Jan 4, 2024 Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop off-the-shelf therapeutics that improve the reach, effectiveness, and access of CAR T cell …See details»
Umoja Biopharma raises $210m to advance next-gen …
Jun 17, 2021 Umoja Biopharma, a preclinical-stage company, is developing an entirely new approach to the therapy. By building an integrated cellular immunotherapy platform, the …See details»
AbbVie and Umoja Biopharma Announce Strategic Collaboration …
Jan 4, 2024 Umoja Biopharma, Inc. is a clinical-stage biotechnology company aiming to develop off-the-shelf therapeutics that improve the reach, effectiveness, and access of CAR T cell …See details»
AbbVie and Umoja Biopharma Announce Strategic Collaboration …
Jan 4, 2024 AbbVie (NYSE: ABBV), and Umoja Biopharma (Umoja), an early clinical-stage biotechnology company, today announced two exclusive option and license agreements to …See details»
Umoja Biopharma Launches with $53M Series A Financing to …
Seattle, Wash., November 18, 2020 – Umoja Biopharma, a biotechnology company pioneering an integrated in vivo immunotherapy platform, today announced the completion of its $53 million …See details»